ArticleJournal of biochemical and molecular toxicology2026
Fibulin-1 Improves Caerulein-Induced Acute Pancreatitis In Vitro by Inhibiting Ferroptosis.
Article in Journal of biochemical and molecular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Acute pancreatitis is an inflammatory disease of the pancreas that is often accompanied by various complications, which seriously impair patient health. Fibulin-1 (FBLN1) is an extracellular matrix (ECM) protein that plays a crucial role in several cellular processes. Previous quantitative analyses of plasma protein profiles of severe acute pancreatitis patients and healthy volunteers have shown that the expression of FBLN1 is decreased in severe acute pancreatitis patients. However, the regulatory roles of FBLN1 in patients with acute pancreatitis have not been fully investigated. In this study, FBLN1 was found to be expressed at lower levels in acute pancreatitis. Moreover, FBLN1 inhibited Caerulein-triggered inflammatory injury in AR42J cells. It was also found that FBLN1 suppressed Caerulein-triggered ferroptosis in AR42J cells, and that FBLN1 could activate the NRF2/HO-1 pathway. In conclusion, FBLN1 may relieve Caerulein-induced acute pancreatitis in AR42J cells by inhibiting ferroptosis, providing insights on the use of FBLN1 in acute pancreatitis treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.